BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. The company announced its 2Q2025 preliminary financial results. The company continues to execute at a high level but faces reimbursement uncertainty. Management continues to fight on that front and plans expansion in product portfolio.
